Quick-start HIV treatment study for people who inject drugs
Part of Immune system & allergy, Infections clinical trials.
This study tests a rapid-start antiretroviral therapy (ART) approach for people who inject drugs and have HIV. The goal is to see if starting HIV medicine quickly helps reduce stigma and improve health outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You inject drugs like opioids, amphetamines, or other injectable drugs (this includes people with opioid use disorder).
- You have HIV and are starting or receiving antiretroviral therapy at one of the study's HIV clinics or at Kajang prison.
- You are at least 18 years old.
- You are willing to give informed consent to participate.
- If you are a clinician, you prescribe HIV medication and are willing to follow the rapid-start protocol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study provides safer, low-dead-space syringes to people who inject drugs to help reduce the spread of infections like HIV and hepatitis C. It is designed for people in low- and middle-income countries who use needle exchange programs.
This study looks at whether starting HIV treatment on the same day you are diagnosed helps reduce stigma and improves engagement in care. It involves interviews and surveys with patients and staff at two clinics in Peru.
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
This study looks at ways to improve HIV prevention and treatment for people on probation who have injected opioids. Researchers want to learn from your experiences to help create better services.
This study offers people leaving jail in Baltimore a switch from daily HIV pills to long-acting shots given every 1–2 months at community clinics. The goal is to make it easier to keep HIV under control after release.
This study tests how well a program combining telemedicine (virtual doctor visits) and peer support can help prevent HIV among people who inject drugs. You'd get trained, attend weekly group sessions, and invite a friend or partner to also take part.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.